HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Liver transplantation for hereditary tyrosinemia type I: analysis of the UNOS database.

Abstract
Patients with HT-1 can develop progressive liver disease and have a high incidence of HCC. LT is indicated in patients with fulminant liver failure, HCC or decompensated chronic liver disease refractory to NTBC. To determine the need for LT and outcomes after LT in children with HT-1. Children with HT-1 who had LT between 10/1987 and 5/2008 were identified from the UNOS database. Of 11,467 children in the UNOS database, 125 (1.1%) required LT secondary to HT-1. Mean age at LT was two and half yr (s.d. ± 3.6 yr). Mean age at LT during the first 10 yr of the study (1.82, s.d. ± 2.86 yr) was significantly lower than in the last decade (3.70, s.d. ± 4.42 yr), p = 0.01. Nearly half of the patients (58, 46.4%) were transplanted between 1988 and 1992. Overall, one- and five-yr patient survival was 90.4% and 90.4%, respectively. LT is a valuable option for children with HT-1 with fulminant liver failure or when medical treatment fails. The rate of LT for children with HT-1 has decreased and age at transplant increased over the last decade most probably reflecting the effect of early diagnosis and treatment with NTBC.
AuthorsRonen Arnon, Rachel Annunziato, Tamir Miloh, Melissa Wasserstein, Hiroshi Sogawa, Monique Wilson, Frederick Suchy, Nanda Kerkar
JournalPediatric transplantation (Pediatr Transplant) Vol. 15 Issue 4 Pg. 400-5 (Jun 2011) ISSN: 1399-3046 [Electronic] Denmark
PMID21504522 (Publication Type: Evaluation Study, Journal Article)
Copyright© 2011 John Wiley & Sons A/S.
Topics
  • Adolescent
  • Chi-Square Distribution
  • Child
  • Databases, Factual
  • Female
  • Follow-Up Studies
  • Graft Rejection
  • Graft Survival
  • Humans
  • Liver Failure (etiology, physiopathology, surgery)
  • Liver Function Tests
  • Liver Transplantation (adverse effects, methods, statistics & numerical data)
  • Male
  • Postoperative Complications (epidemiology, physiopathology)
  • Retrospective Studies
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome
  • Tyrosinemias (complications, diagnosis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: